Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOFAC: Omalizumab in Food Allergic Children
NCT04037176Phase 4Completed
- Start
- Nov 2019
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in food allergy comparing Omalizumab with Placebo (2 arms). Primary endpoint: Change in challenge threshold (mg food protein tolerated by oral intake) at 3 months. Started Nov 2019; status: completed.
02
Drugs
omalizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT04037176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037176.